New Developments in Cardiac Regeneration

Heart Lung and Circulation

Volumn 26, Issue 4, 2017, Pages 316-322

  Le, Thi Yen Loan ^a,b   Thavapalachandran, Sujitha ^a,b,c   Kizana, Eddy ^a,b,c   Chong, James JH ^a,b,c  

^a WESTMEAD HOSPITAL   (Australia)

^b WESTMEAD HOSPITAL   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Adult stem cells; Cell transplantation; Heart failure; Myocardial infarction; Non cell strategies; Pluripotent stem cells; Regeneration

Indexed keywords

CYTOKINE; ERYTHROPOIETIN; GRANULOCYTE COLONY STIMULATING FACTOR; MICRORNA; MONOCYTE CHEMOTACTIC PROTEIN 3; PLACENTAL GROWTH FACTOR; PROSTAGLANDIN F; STROMAL CELL DERIVED FACTOR 1; THYMOSIN BETA4; TRANSCRIPTION FACTOR; VASCULOTROPIN;

ADULT STEM CELL; BONE MARROW DERIVED MONONUCLEAR CELL; CARDIAC MUSCLE CELL; CARDIAC STEM CELL; CELL REPROGRAMMING TECHNIQUE; CELL TRANSDIFFERENTIATION; ENGRAFTMENT; EXOSOME; HEART FAILURE; HEART INFARCTION; HUMAN; HUMAN EMBRYONIC STEM CELL; INDUCED PLURIPOTENT STEM CELL; ISCHEMIC CARDIOMYOPATHY; MESENCHYMAL STROMA CELL; MULTIPOTENT STEM CELL; NONHUMAN; REGENERATIVE MEDICINE; REVIEW; SKELETAL MYOBLAST; STEM CELL MOBILIZATION; STEM CELL TRANSPLANTATION; TISSUE ENGINEERING; TISSUE REGENERATION; TISSUE REPAIR; ADULT; HEART LEFT VENTRICLE FUNCTION; MESENCHYMAL STEM CELL TRANSPLANTATION; PATHOPHYSIOLOGY; PLURIPOTENT STEM CELL; PROCEDURES; TRANSPLANTATION;

ADULT; ADULT STEM CELLS; HEART FAILURE; HUMANS; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; PLURIPOTENT STEM CELLS; REGENERATIVE MEDICINE; VENTRICULAR FUNCTION, LEFT;

EID: 85007436580     PISSN: 14439506     EISSN: 14442892     Source Type: Journal    
DOI: 10.1016/j.hlc.2016.11.002     Document Type: Review

References (88)

1. [1] Nichols M, P.K., Alston, L., Allender, S., Australian heart disease statistics 2014. 2014, National Heart Foundation of Australia, Melbourne.
2. [2] Go, A.S., Mozaffarian, D., Roger, V.L., Benjamin, E.J., Berry, J.D., Blaha, M.J., et al. Heart disease and stroke statistics-2014 update: a report from the American Heart Association. Circulation 129:3 (2014), e28–e292.
3. [3] Zamilpa, R., Navarro, M.M., Flores, I., Griffey, S., Stem cell mechanisms during left ventricular remodeling post-myocardial infarction: Repair and regeneration. World J Cardiol 6:7 (2014), 610–620.
4. [4] Go, A.S., Mozaffarian, D., Roger, V.L., Benjamin, E.J., Berry, J.D., Borden, W.B., et al. Executive summary: heart disease and stroke statistics-2013 update: a report from the American Heart Association. Circulation 127:1 (2013), 143–152.
5. [5] Group TCTS. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group. N Engl J Med 316:23 (1987), 1429–1435.
6. [6] Packer, M., Bristow, M.R., Cohn, J.N., Colucci, W.S., Fowler, M.B., Gilbert, E.M., et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med 334:21 (1996), 1349–1355.
7. [7] Pitt, B., Zannad, F., Remme, W.J., Cody, R., Castaigne, A., Perez, A., et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341:10 (1999), 709–717.
8. [8] Cohn, J.N., Tognoni, G., Valsartan Heart Failure Trial I. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 345:23 (2001), 1667–1675.
9. [9] Bristow, M.R., Saxon, L.A., Boehmer, J., Krueger, S., Kass, D.A., De Marco, T., et al. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med 350:21 (2004), 2140–2150.
10. [10] Bardy, G.H., Lee, K.L., Mark, D.B., Poole, J.E., Packer, D.L., Boineau, R., et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 352:3 (2005), 225–237.
11. [11] McMurray, J.J., Packer, M., Desai, A.S., Gong, J., Lefkowitz, M.P., Rizkala, A.R., et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 371:11 (2014), 993–1004.
12. [12] Cohn, J.N., Johnson, G., Ziesche, S., Cobb, F., Francis, G., Tristani, F., et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 325:5 (1991), 303–310.
13. [13] Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N Engl J Med 325:5 (1991), 293–302.
14. [14] Chong, J.J., Cell therapy for left ventricular dysfunction: an overview for cardiac clinicians. Heart Lung Circ 21:9 (2012), 532–542.
15. [15] Aicher, A., Brenner, W., Zuhayra, M., Badorff, C., Massoudi, S., Assmus, B., et al. Assessment of the tissue distribution of transplanted human endothelial progenitor cells by radioactive labeling. Circulation 107:16 (2003), 2134–2139.
16. [16] Blocklet, D., Toungouz, M., Berkenboom, G., Lambermont, M., Unger, P., Preumont, N., et al. Myocardial homing of nonmobilized peripheral-blood CD34+ cells after intracoronary injection. Stem Cells 24:2 (2006), 333–336.
17. [17] Hofmann, M., Wollert, K.C., Meyer, G.P., Menke, A., Arseniev, L., Hertenstein, B., et al. Monitoring of bone marrow cell homing into the infarcted human myocardium. Circulation 111:17 (2005), 2198–2202.
18. [18] Sanganalmath, S.K., Bolli, R., Cell therapy for heart failure: a comprehensive overview of experimental and clinical studies, current challenges, and future directions. Circ Res 113:6 (2013), 810–834.
19. [19] Tse, H.F., Siu, C.W., Zhu, S.G., Songyan, L., Zhang, Q.Y., Lai, W.H., et al. Paracrine effects of direct intramyocardial implantation of bone marrow derived cells to enhance neovascularization in chronic ischaemic myocardium. Eur J Heart Fail 9:8 (2007), 747–753.
20. [20] Gnecchi, M., Zhang, Z., Ni, A., Dzau, V.J., Paracrine mechanisms in adult stem cell signaling and therapy. Circ Res 103:11 (2008), 1204–1219.
21. [21] Ibrahim, A.G., Cheng, K., Marban, E., Exosomes as critical agents of cardiac regeneration triggered by cell therapy. Stem Cell Reports 2:5 (2014), 606–619.
22. [22] Mias, C., Lairez, O., Trouche, E., Roncalli, J., Calise, D., Seguelas, M.H., et al. Mesenchymal stem cells promote matrix metalloproteinase secretion by cardiac fibroblasts and reduce cardiac ventricular fibrosis after myocardial infarction. Stem Cells 27:11 (2009), 2734–2743.
23. [23] Meyer, G.P., Wollert, K.C., Lotz, J., Pirr, J., Rager, U., Lippolt, P., et al. Intracoronary bone marrow cell transfer after myocardial infarction: 5-year follow-up from the randomized-controlled BOOST trial. Eur Heart J 30:24 (2009), 2978–2984.
24. [24] Taniguchi, N., Nakamura, T., Sawada, T., Matsubara, K., Furukawa, K., Hadase, M., et al. Erythropoietin prevention trial of coronary restenosis and cardiac remodeling after ST-elevated acute myocardial infarction (EPOC-AMI): a pilot, randomized, placebo-controlled study. Circ J 74:11 (2010), 2365–2371.
25. [25] Achilli, F., Malafronte, C., Lenatti, L., Gentile, F., Dadone, V., Gibelli, G., et al. Granulocyte colony-stimulating factor attenuates left ventricular remodelling after acute anterior STEMI: results of the single-blind, randomized, placebo-controlled multicentre STem cEll Mobilization in Acute Myocardial Infarction (STEM-AMI) Trial. Eur J Heart Fail 12:10 (2010), 1111–1121.
26. [26] Leistner, D.M., Fischer-Rasokat, U., Honold, J., Seeger, F.H., Schachinger, V., Lehmann, R., et al. Transplantation of progenitor cells and regeneration enhancement in acute myocardial infarction (TOPCARE-AMI): final 5-year results suggest long-term safety and efficacy. Clin Res Cardiol 100:10 (2011), 925–934.
27. [27] Makkar, R.R., Smith, R.R., Cheng, K., Malliaras, K., Thomson, L.E., Berman, D., et al. Intracoronary cardiosphere-derived cells for heart regeneration after myocardial infarction (CADUCEUS): a prospective, randomised phase 1 trial. Lancet 379:9819 (2012), 895–904.
28. [28] Houtgraaf, J.H., den Dekker, W.K., van Dalen, B.M., Springeling, T., de Jong, R., van Geuns, R.J., et al. First experience in humans using adipose tissue-derived regenerative cells in the treatment of patients with ST-segment elevation myocardial infarction. J Am Coll Cardiol 59:5 (2012), 539–540.
29. [29] Bolli, R., Chugh, A.R., D'Amario, D., Loughran, J.H., Stoddard, M.F., Ikram, S., et al. Cardiac stem cells in patients with ischaemic cardiomyopathy (SCIPIO): initial results of a randomised phase 1 trial. Lancet 378:9806 (2011), 1847–1857.
30. [30] Bartunek, J., Behfar, A., Dolatabadi, D., Vanderheyden, M., Ostojic, M., Dens, J., et al. Cardiopoietic stem cell therapy in heart failure: the C-CURE (Cardiopoietic stem Cell therapy in heart failURE) multicenter randomized trial with lineage-specified biologics. J Am Coll Cardiol 61:23 (2013), 2329–2338.
31. [31] Schachinger, V., Erbs, S., Elsasser, A., Haberbosch, W., Hambrecht, R., Holschermann, H., et al. Intracoronary bone marrow-derived progenitor cells in acute myocardial infarction. N Engl J Med 355:12 (2006), 1210–1221.
32. [32] Fisher, S.A., Doree, C., Mathur, A., Martin-Rendon, E., Meta-analysis of cell therapy trials for patients with heart failure. Circ Res 116:8 (2015), 1361–1377.
33. [33] Gyongyosi, M., Wojakowski, W., Lemarchand, P., Lunde, K., Tendera, M., Bartunek, J., et al. Meta-Analysis of Cell-based CaRdiac stUdiEs (ACCRUE) in patients with acute myocardial infarction based on individual patient data. Circ Res 116:8 (2015), 1346–1360.
34. [34] Abdel-Latif, A., Bolli, R., Tleyjeh, I.M., Montori, V.M., Perin, E.C., Hornung, C.A., et al. Adult bone marrow-derived cells for cardiac repair: a systematic review and meta-analysis. Arch Intern Med 167:10 (2007), 989–997.
35. [35] Burridge, P.W., Keller, G., Gold, J.D., Wu, J.C., Production of de novo cardiomyocytes: human pluripotent stem cell differentiation and direct reprogramming. Cell Stem Cell 10:1 (2012), 16–28.
36. [36] Chong, J.J., Yang, X., Don, C.W., Minami, E., Liu, Y.W., Weyers, J.J., et al. Human embryonic-stem-cell-derived cardiomyocytes regenerate non-human primate hearts. Nature 510:7504 (2014), 273–277.
37. [37] Chong, J.J., Murry, C.E., Cardiac regeneration using pluripotent stem cells-progression to large animal models. Stem Cell Res 13:3 Pt B (2014), 654–665.
38. [38] Shiba, Y., Fernandes, S., Zhu, W.Z., Filice, D., Muskheli, V., Kim, J., et al. Human ES-cell-derived cardiomyocytes electrically couple and suppress arrhythmias in injured hearts. Nature 489:7415 (2012), 322–325.
39. [39] Laflamme, M.A., Chen, K.Y., Naumova, A.V., Muskheli, V., Fugate, J.A., Dupras, S.K., et al. Cardiomyocytes derived from human embryonic stem cells in pro-survival factors enhance function of infarcted rat hearts. Nat Biotechnol 25:9 (2007), 1015–1024.
40. [40] Thies, R.S., Murry, C.E., The advancement of human pluripotent stem cell-derived therapies into the clinic. Development 142:18 (2015), 3077–3084.
41. [41] Lee, A.S., Tang, C., Rao, M.S., Weissman, I.L., Wu, J.C., Tumorigenicity as a clinical hurdle for pluripotent stem cell therapies. Nat Med 19:8 (2013), 998–1004.
42. [42] Orlic, D., Kajstura, J., Chimenti, S., Jakoniuk, I., Anderson, S.M., Li, B., et al. Bone marrow cells regenerate infarcted myocardium. Nature 410:6829 (2001), 701–705.
43. [43] Murry, C.E., Soonpaa, M.H., Reinecke, H., Nakajima, H., Nakajima, H.O., Rubart, M., et al. Haematopoietic stem cells do not transdifferentiate into cardiac myocytes in myocardial infarcts. Nature 428:6983 (2004), 664–668.
44. [44] Balsam, L.B., Wagers, A.J., Christensen, J.L., Kofidis, T., Weissman, I.L., Robbins, R.C., Haematopoietic stem cells adopt mature haematopoietic fates in ischaemic myocardium. Nature 428:6983 (2004), 668–673.
45. [45] Nygren, J.M., Jovinge, S., Breitbach, M., Sawen, P., Roll, W., Hescheler, J., et al. Bone marrow-derived hematopoietic cells generate cardiomyocytes at a low frequency through cell fusion, but not transdifferentiation. Nat Med 10:5 (2004), 494–501.
46. [46] Reinecke, H., Poppa, V., Murry, C.E., Skeletal muscle stem cells do not transdifferentiate into cardiomyocytes after cardiac grafting. J Mol Cell Cardiol 34:2 (2002), 241–249.
47. [47] Reinecke, H., MacDonald, G.H., Hauschka, S.D., Murry, C.E., Electromechanical coupling between skeletal and cardiac muscle. Implications for infarct repair. J Cell Biol. 149:3 (2000), 731–740.
48. [48] Francis, D.P., Mielewczik, M., Zargaran, D., Cole, G.D., Autologous bone marrow-derived stem cell therapy in heart disease: discrepancies and contradictions. Int J Cardiol 168:4 (2013), 3381–3403.
49. [49] Nowbar, A.N., Mielewczik, M., Karavassilis, M., Dehbi, H.M., Shun-Shin, M.J., Jones, S., et al. Discrepancies in autologous bone marrow stem cell trials and enhancement of ejection fraction (DAMASCENE): weighted regression and meta-analysis. BMJ, 348, 2014, g2688.
50. [50] Rehman, J., Bone marrow tinctures for cardiovascular disease: lost in translation. Circulation 127:19 (2013), 1935–1937.
51. [51] Beltrami, A.P., Barlucchi, L., Torella, D., Baker, M., Limana, F., Chimenti, S., et al. Adult cardiac stem cells are multipotent and support myocardial regeneration. Cell 114:6 (2003), 763–776.
52. [52] Ellison, G.M., Vicinanza, C., Smith, A.J., Aquila, I., Leone, A., Waring, C.D., et al. Adult c-kit(pos) cardiac stem cells are necessary and sufficient for functional cardiac regeneration and repair. Cell 154:4 (2013), 827–842.
53. [53] van Berlo, J.H., Kanisicak, O., Maillet, M., Vagnozzi, R.J., Karch, J., Lin, S.C., et al. c-kit+ cells minimally contribute cardiomyocytes to the heart. Nature 509:7500 (2014), 337–341.
54. [54] Sultana, N., Zhang, L., Yan, J., Chen, J., Cai, W., Razzaque, S., et al. Resident c-kit(+) cells in the heart are not cardiac stem cells. Nat Commun, 6, 2015 Oct 30, 8701, 10.1038/ncomms9701.
55. [55] Keith, M.C., Bolli, R., String theory” of c-kit(pos) cardiac cells: a new paradigm regarding the nature of these cells that may reconcile apparently discrepant results. Circ Res 116:7 (2015), 1216–1230.
56. [56] Bolli, R., Chugh, A.R., D'Amario, D., Loughran, J.H., Stoddard, M.F., Ikram, S., et al. Cardiac stem cells in patients with ischaemic cardiomyopathy (SCIPIO): initial results of a randomised phase 1 trial. Lancet 378:9806 (2013), 1847–1857.
57. [57] The Lancet, E., Expression of concern: the SCIPIO trial. Lancet, 383(9925), 2014, 1279.
58. [58] Malliaras, K., Makkar, R.R., Smith, R.R., Cheng, K., Wu, E., Bonow, R.O., et al. Intracoronary cardiosphere-derived cells after myocardial infarction: evidence of therapeutic regeneration in the final 1-year results of the CADUCEUS trial (CArdiosphere-Derived aUtologous stem CElls to reverse ventricUlar dySfunction). J Am Coll Cardiol 63:2 (2014), 110–122.
59. [59] Andersen, D.C., Andersen, P., Schneider, M., Jensen, H.B., Sheikh, S.P., Murine “cardiospheres” are not a source of stem cells with cardiomyogenic potential. Stem Cells 27:7 (2009), 1571–1581.
60. [60] Kattman, S.J., Witty, A.D., Gagliardi, M., Dubois, N.C., Niapour, M., Hotta, A., et al. Stage-specific optimization of activin/nodal and BMP signaling promotes cardiac differentiation of mouse and human pluripotent stem cell lines. Cell Stem Cell 8:2 (2011), 228–240.
61. [61] Lian, X., Zhang, J., Azarin, S.M., Zhu, K., Hazeltine, L.B., Bao, X., et al. Directed cardiomyocyte differentiation from human pluripotent stem cells by modulating Wnt/beta-catenin signaling under fully defined conditions. Nat Protoc 8:1 (2013), 162–175.
62. [62] Bedada, F.B., Wheelwright, M., Metzger, J.M., Maturation status of sarcomere structure and function in human iPSC-derived cardiac myocytes. Biochim Biophys Acta 1863:7 Pt B (2016), 1829–1838.
63. [63] Zhang, J., Wilson, G.F., Soerens, A.G., Koonce, C.H., Yu, J., Palecek, S.P., et al. Functional cardiomyocytes derived from human induced pluripotent stem cells. Circ Res 104:4 (2009), e30–e41.
64. [64] Robertson, C., Tran, D.D., George, S.C., Concise review: maturation phases of human pluripotent stem cell-derived cardiomyocytes. Stem Cells 31:5 (2013), 829–837.
65. [65] Mummery, C., Ward-van Oostwaard, D., Doevendans, P., Spijker, R., van den Brink, S., Hassink, R., et al. Differentiation of human embryonic stem cells to cardiomyocytes: role of coculture with visceral endoderm-like cells. Circulation 107:21 (2003), 2733–2740.
66. [66] Synnergren, J., Ameen, C., Jansson, A., Sartipy, P., Global transcriptional profiling reveals similarities and differences between human stem cell-derived cardiomyocyte clusters and heart tissue. Physiol Genomics 44:4 (2012), 245–258.
67. [67] Mummery, C.L., Zhang, J., Ng, E.S., Elliott, D.A., Elefanty, A.G., Kamp, T.J., Differentiation of human embryonic stem cells and induced pluripotent stem cells to cardiomyocytes: a methods overview. Circ Res 111:3 (2012), 344–358.
68. [68] Pillekamp, F., Haustein, M., Khalil, M., Emmelheinz, M., Nazzal, R., Adelmann, R., et al. Contractile properties of early human embryonic stem cell-derived cardiomyocytes: beta-adrenergic stimulation induces positive chronotropy and lusitropy but not inotropy. Stem Cells Dev 21:12 (2012), 2111–2121.
69. [69] Poon, E., Kong, C.W., Li, R.A., Human pluripotent stem cell-based approaches for myocardial repair: from the electrophysiological perspective. Mol Pharm 8:5 (2011), 1495–1504.
70. [70] van Laake, L.W., Passier, R., Doevendans, P.A., Mummery, C.L., Human embryonic stem cell-derived cardiomyocytes and cardiac repair in rodents. Circ Res 102:9 (2008), 1008–1010.
71. [71] Feric, N.T., Radisic, M., Maturing human pluripotent stem cell-derived cardiomyocytes in human engineered cardiac tissues. Adv Drug Deliv Rev 96 (2016), 110–134.
72. [72] Schram, G., Pourrier, M., Melnyk, P., Nattel, S., Differential distribution of cardiac ion channel expression as a basis for regional specialization in electrical function. Circ Res 90:9 (2002), 939–950.
73. [73] van Veen, A.A., van Rijen, H.V., Opthof, T., Cardiac gap junction channels: modulation of expression and channel properties. Cardiovasc Res 51:2 (2001), 217–229.
74. [74] Menasche, P., Vanneaux, V., Hagege, A., Bel, A., Cholley, B., Cacciapuoti, I., et al. Human embryonic stem cell-derived cardiac progenitors for severe heart failure treatment: first clinical case report. Eur Heart J 36:30 (2015), 2011–2017.
75. [75] Zhou, B., Honor, L.B., Ma, Q., Oh, J.H., Lin, R.Z., Melero-Martin, J.M., et al. Thymosin beta 4 treatment after myocardial infarction does not reprogram epicardial cells into cardiomyocytes. J Mol Cell Cardiol 52:1 (2012), 43–47.
76. [76] Schenk, S., Mal, N., Finan, A., Zhang, M., Kiedrowski, M., Popovic, Z., et al. Monocyte chemotactic protein-3 is a myocardial mesenchymal stem cell homing factor. Stem Cells 25:1 (2007), 245–251.
77. [77] Iwasaki, H., Kawamoto, A., Tjwa, M., Horii, M., Hayashi, S., Oyamada, A., et al. PlGF repairs myocardial ischemia through mechanisms of angiogenesis, cardioprotection and recruitment of myo-angiogenic competent marrow progenitors. PLoS One, 6(9), 2011, e24872.
78. [78] Smart, N., Risebro, C.A., Melville, A.A., Moses, K., Schwartz, R.J., Chien, K.R., et al. Thymosin beta4 induces adult epicardial progenitor mobilization and neovascularization. Nature 445:7124 (2007), 177–182.
79. [79] Qian, L., Huang, Y., Spencer, C.I., Foley, A., Vedantham, V., Liu, L., et al. In vivo reprogramming of murine cardiac fibroblasts into induced cardiomyocytes. Nature 485:7400 (2012), 593–598.
80. [80] Muraoka, N., Ieda, M., Direct reprogramming of fibroblasts into myocytes to reverse fibrosis. Annu Rev Physiol 76 (2014), 21–37.
81. [81] Doppler, S.A., Deutsch, M.A., Lange, R., Krane, M., Direct Reprogramming-The Future of Cardiac Regeneration?. Int J Mol Sci 16:8 (2015), 17368–17393.
82. [82] Banerjee, I., Fuseler, J.W., Price, R.L., Borg, T.K., Baudino, T.A., Determination of cell types and numbers during cardiac development in the neonatal and adult rat and mouse. Am J Physiol Heart Circ Physiol 293:3 (2007), H1883–H1891.
83. [83] Masumoto, H., Matsuo, T., Yamamizu, K., Uosaki, H., Narazaki, G., Katayama, S., et al. Pluripotent stem cell-engineered cell sheets reassembled with defined cardiovascular populations ameliorate reduction in infarct heart function through cardiomyocyte-mediated neovascularization. Stem Cells 30:6 (2012), 1196–1205.
84. [84] Zhang, D., Huang, W., Dai, B., Zhao, T., Ashraf, A., Millard, R.W., et al. Genetically manipulated progenitor cell sheet with diprotin A improves myocardial function and repair of infarcted hearts. Am J Physiol Heart Circ Physiol 299:5 (2010), H1339–H1347.
85. [85] Kobayashi, H., Shimizu, T., Yamato, M., Tono, K., Masuda, H., Asahara, T., et al. Fibroblast sheets co-cultured with endothelial progenitor cells improve cardiac function of infarcted hearts. J Artif Organs 11:3 (2008), 141–147.
86. [86] Garbern, J.C., Lee, R.T., Cardiac stem cell therapy and the promise of heart regeneration. Cell Stem Cell 12:6 (2013), 689–698.
87. [87] Gallet, R., Dawkins, J., Valle, J., Simsolo, E., de Couto, G., Middleton, R., et al. Exosomes secreted by cardiosphere-derived cells reduce scarring, attenuate adverse remodelling, and improve function in acute and chronic porcine myocardial infarction. Eur Heart J, 2016.
88. [88] Khan, M., Nickoloff, E., Abramova, T., Johnson, J., Verma, S.K., Krishnamurthy, P., et al. Embryonic stem cell-derived exosomes promote endogenous repair mechanisms and enhance cardiac function following myocardial infarction. Circ Res 117:1 (2015), 52–64.